Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) — Tangible Net Worth Ratio
Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has a Tangible Net Worth Ratio of 96.8% as of June 2025. This metric is calculated by deducting intangible assets (CN¥61.64 Million) from net assets (CN¥1.92 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See what is Suzhou Fushilai Pharmaceutical Co. Ltd.'s book value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Suzhou Fushilai Pharmaceutical Co. Ltd. Tangible Net Worth Ratio (2019–2024)
This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s Tangible Net Worth Ratio has changed across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 96.8%, reflecting net assets of CN¥1.92 Billion with intangible assets of CN¥61.64 Million CNY. Also explore Suzhou Fushilai Pharmaceutical Co. Ltd. net asset momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024, covering 6 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 301258 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 96.7% | CN¥1.89 Billion | CN¥62.56 Million | CN¥2.09 Billion | ▼ -2.2 pp |
| 2023 | 98.9% | CN¥1.95 Billion | CN¥21.24 Million | CN¥2.12 Billion | ▲ +0.1 pp |
| 2022 | 98.8% | CN¥1.89 Billion | CN¥21.97 Million | CN¥2.10 Billion | ▲ +1.8 pp |
| 2021 | 97.0% | CN¥742.84 Million | CN¥22.07 Million | CN¥970.31 Million | ▲ +0.7 pp |
| 2020 | 96.4% | CN¥622.64 Million | CN¥22.70 Million | CN¥788.25 Million | ▲ +0.3 pp |
| 2019 | 96.1% | CN¥581.96 Million | CN¥22.78 Million | CN¥751.44 Million | — |